Abstract Submission Criteria

HomeProgramCall for Abstracts ▶ Abstract Submission Criteria

Abstract Content

Scientific Abstracts:

Your scientific abstract must contain:

  1. A descriptive title, list of authors and institutions;
  2. An introduction/rationale to the study;
  3. The methods used;
  4. The results of the study including new data not previously published or presented at a major national or international meeting;
  5. Conclusions of the study. It is not satisfactory to state: "The results will be discussed."

Abstracts reporting results of meta-analyses and systematic reviews will also be considered.

ALL ABSTRACTS NOT MEETING THESE MINIMUM CRITERIA WILL NOT BE ACCEPTED. It is recommended that the abstract content be organized with the following headings:  RATIONALE, METHODS, RESULTS, AND CONCLUSIONS.

Case Reports:

Interesting and unique case reports will be considered for presentation at the ATS International Conference. Abstracts may describe a single case report or a series of associated cases. Case report abstracts must contain the following four components:

  1. A descriptive title, list of authors and institutions;
  2. An introduction
  3. A description of the actual case report(s)
  4. A discussion of the novelty and importance of the case(s)


Submission Fee:

The Presenting Author will be charged a non-refundable processing fee for each abstract, based on their membership status, as follows:

Member Non-Member
Scientific Abstract: $62 $85
Case Report Abstract: $32 $45
Low Income Country**: $20 $20

**International Low Income fee is for Members and Non-Members residing in countries with a Gross National Product per capita of less than $3000. View list of countries to determine your submission fee.

Please Note

  • Completing your payment is necessary to submit your abstract. Your payment may be submitted electronically using a credit card on a safe and secure site.
  • The abstract submission fee is not refundable, even if the abstract is not accepted.


The abstract must be submitted in English. If accepted, the abstract must be presented in English.


  • Each abstract should have a distinctive hypothesis or include a unique methodology that is clearly differentiated from the other abstracts submitted by a single research group.
  • An abstract that fails to meet these criteria will be considered a duplicate.
  • Duplicate abstracts from a single research group will be rejected.

Prior Publication:

Abstracts are not to be submitted for consideration if the work covered is to be published or presented at a major national or international meeting prior to the 2021 ATS International Conference. Abstracts of work presented at local or regional meetings may be submitted for consideration. If the abstract is only presented at a local meeting that abstract should not be posted on a publicly available website (or appear in another journal prior to the ATS Conference, even if it is just the abstract that is being published).

Embargo Policy:

It is the policy of the ATS that all scientific research-related content included in an abstract to be presented at the ATS International Conference be withheld until after the abstract has been presented at the conference. This includes all interim and final results, whether or not endpoints were met and any other data that would indicate study results.

Exceptions will be granted on a case-by-case basis if:

• the company in question can demonstrate that it is legally-mandated to issue a news release prior to the conference


• study results have been submitted to ClinicalTrials.gov.

Data or numbers should not be included in a news release; the scientific content should include only legally required information.

The research-related content of the release should also state that the final results will be presented at the ATS International Conference, if that information has been confirmed.

Any questions about the policy should be directed to Dacia Morris, Director, Communications and Marketing, at dmorris@thoracic.org or 212-315-8620.

Research Funding Source:

All abstracts must specify funding source: i.e., pharmaceutical firm name, grant name and source or other specific funding source. Compliance to this rule is a prerequisite for review. Abstracts of research funded by tobacco industry sources (whole or in part) will not be considered. If you have no specific funding source, please indicate "none."


The person submitting the abstract will automatically be the Presenting Author. The Presenting Author will be listed first.

The Presenting Author cannot be modified for any reason after December 16, 2020.

The submitter (Presenting Author) is responsible for ensuring that all co-authors have agreed to be listed on the abstract and have knowledge of the abstract submission.


The Presenting Author of this abstract must complete the 2021 Abstract Author Disclosure Questions. All financial support received from commercial entities for the work submitted must be declared, as well as any other personal financial interests that could be perceived as a potential conflict of interest relevant to the work submitted. Examples include any payment received from or investments held in companies that are relevant to the subject matter of the abstract, and any patents or other intellectual property that could be perceived to be affected financially by the outcome of the work submitted. Authors are also required by ATS to disclose all payments or services received from the tobacco industry, vaping industry, and cannabis entities that promote recreational use and/or non-evidence-based uses of inhaled cannabis products for any purpose. Abstracts of research supported by tobacco industry sources or cannabis entities that promote recreational use and/or non-evidence-based uses of inhaled cannabis products for any purpose, will not be considered for acceptance. Abstract authors affiliated with a tobacco industry entity, or a cannabis entity that promotes recreational use and/or non-evidence-based uses of inhaled cannabis for any purpose, at any time during the twelve months preceding the 2021 ATS conference (or during the conference or if expected to be affiliated by the end of 2021) are also ineligible to participate as planners or speakers for ATS 2021 sessions including all scientific symposia and courses. Involvement with non-tobacco nicotine delivery products does not automatically exclude a person from ATS roles, including acceptance of conference abstracts, unless the entity is involved is tobacco industry-related.

Abstract Length:

The total word count of an abstract may not exceed 400 words. Note: The 400-word count is for the abstract body (title, authors' information, institutions, tables, images and spaces between words will not count towards the 400 word count).


Responsibility for accuracy rests with the Presenting Author.


When using abbreviations, spell the full name out on first mention and follow with the abbreviation in parentheses. Do not abbreviate compounds in the title of the abstract. Use of unfamiliar abbreviations may be grounds for rejection unless definitions are supplied in the abstract.


A maximum of 1 Table OR 1 figure can be included per abstract in JPG format only. When including a table it is recommended to save the table as an image and then upload it in to the abstract body. The image will not count towards the 400 word count. Please note: If you choose to include a high-quality table or figure, make sure it is legible (for review and publication).

Category for both Scientific and Case Report Abstracts:

There will be a step-by-step process to complete when choosing a category and review group:

1. choose the type;
2. choose the classification;
3. choose the discipline;
4. choose the subclassification;
5. choose reviewing Assembly.

Abstract Scholarships:

To be considered for an Abstract Scholarship to the International Conference it is essential that you meet the criteria described on the ATS Awards site: http://www.thoracic.org/members/assemblies/ats-abstract-scholarships.php. If criteria described on the ATS website can be met by the applicant, please proceed to check the box in the Affirmations section of the online submission program.


You can log off at any time without submitting your abstract and return to continue your work at another time. As long as you do not formally submit the abstract, it can be edited and revised online as many times as you wish but before the deadline.

If you wish to withdraw your submitted abstract before the deadline Wednesday, Dec. 16, 2020 (5 p.m. ET), follow these steps:

  • Log in to the submission system
  • Click on the abstract title.
  • Click Review My Work and scroll to the end of page.
  • Click on Delete this Submission button.
  • Abstract submission fee is non-refundable.

To withdraw the abstract after the deadline Wednesday, Dec. 16, 2020: Presenting Author must contact support staff via email at ats@support.ctimeetingtech.com.  Provide the abstract ID# and title.  No abstracts will be withdrawn after Jan. 4, 2021

If a correction is required to your submitted abstract before the deadline Wednesday, Dec. 16, 2020 (5 p.m. ET), follow these steps:

  • Log in to the submission system.
  • Click on the abstract title.
  • Click Review My Work and scroll to the end of page.
  • Click on Delete this Submission button.
  • Then re-submit by clicking the +New button.

Please note that you will be required to pay the fee for a new submission and the fee for the previous submission will not be refunded.

No corrections will be allowed after the deadline: Wednesday, Dec. 16, 2020, 5 p.m., ET.

Please proofread and edit your abstract carefully before submission!


  • Abstracts that meet acceptable scientific and ethical standards and that contain data not previously published or presented will be considered.
  • The International Conference Committee reserves the right to reject abstracts based not only on fulfilling submission criteria, but also on relative merit and the special scheduling requirements of the Conference
  • You are allowed to state your presentation preference, however, the International Conference Committee will decide on the presentation format of all accepted abstracts (oral or poster).  The decision of the presentation format is final.
  • All Committee decisions regarding abstract schedule and presentation format are final.

Abstract Presentation

  • The Presenting Author (submitter) of accepted abstracts will be expected to present the study.
  • Information on the session format of an accepted abstract will be emailed to the Presenting Author.

Email Notification

  • Notification of abstract acceptance or rejection will be sent electronically to the Presenting Author in March 2021 at the email address provided in the online submission. Please note: Check both your inbox and junk mail folder for your email notification.
  • It is the responsibility of the Presenting Author to ensure that the email address is correct because correspondence relating to the abstract will be sent to this address.
  • If you have not received notification by the end of March 2021, please contact ats@support.ctimeetingtech.com or conference@thoracic.org..


All accepted abstracts will be published by the American Thoracic Society in the Online Abstract Issue in May 2021. Final decision regarding publication of other abstracts is the responsibility of the ATS International Conference Committee.

Accepted abstracts will also be available in the Online Program Itinerary and Mobile App as follows:

  • Online Program Itinerary in April 2021 *
  • Mobile App – May 2021 *
* subject to change

Submission Guide

This section contains information to guide you through the online submission process. We recommend that you print this page and use it as a reference during this process.

  • Click the steps on the left side of the screen and complete each section. Be sure to carefully follow the instructions within each section.
  • Save your work by clicking Save and Continue button. This does not submit your abstract for review. Be sure to save your work before logging off the site.
  • You can log off at any time without submitting your abstract and return to continue your work at another time. As long as you do not submit the abstract, it can be edited and revised online as many times as needed.
  • Add codes for any special formatting, symbols, and any Greek characters using the Special Character Chart link.
  • Verify that your abstract is correct by clicking Review My Work.
  • Print out and proofread the abstract preview to verify that it is correct before completing the submission process. REMEMBER: Once you complete the submission process, an additional fee will be required to re-submit a new abstract.
  • Click on Finalize and Submit button, but ONLY when you are sure that your abstract is complete and in final form.
  • Payment of the submission fee must be completed on the credit card screen to complete submission of your abstract.

For tech support, please contact:
Email: ats@support.ctimeetingtech.com
Phone: 217-398-1792*

*(8 a.m. - 5 p.m. ET, USA, Monday - Friday).

Deadline: All abstracts must be submitted by
Wednesday, Dec 16, 2020, 5 p.m. ET
If not submitted by this date, your abstract will not be considered.